Madrigal extends MASH deal streak with Arrowhead drug that J&J didn’t wantnews2026-05-05T13:25:50+00:00May 5th, 2026|Endpoints News|
Healthcare organizations are increasingly building their own AI toolsnews2026-05-05T13:12:44+00:00May 5th, 2026|Endpoints News|
Cytokinetics succeeds where Bristol Myers failed in heart muscle diseasenews2026-05-05T11:30:51+00:00May 5th, 2026|Endpoints News|
Vertex drops mRNA cystic fibrosis program over ‘tolerability’ issuesnews2026-05-04T23:29:58+00:00May 4th, 2026|Endpoints News|
FDA search for new CBER head focused on small group of final candidatesnews2026-05-04T16:36:11+00:00May 4th, 2026|Endpoints News|
Supreme Court restores mifepristone access by mailnews2026-05-04T16:14:14+00:00May 4th, 2026|Endpoints News|
Celcuity’s breast cancer win; Odyssey plans $205M IPOnews2026-05-04T14:54:24+00:00May 4th, 2026|Endpoints News|
Biotech has a new startup model: Small team, big check and Chinese assetsnews2026-05-04T14:30:39+00:00May 4th, 2026|Endpoints News|
Windward Bio gets $165M to take China-derived drug into Phase 3 asthma trialnews2026-05-04T13:03:57+00:00May 4th, 2026|Endpoints News|
UCB bets $2 billion on Candid’s T cell engager ambitionsnews2026-05-04T01:54:30+00:00May 4th, 2026|Endpoints News|
